Gland Pharma Receives USFDA Approval for Methylprednisolone Injectable

USFDA approval secured for Methylprednisolone Acetate Injection.
USD 214 million target market size as of August 2026.

Reader Takeaway: New US market access expands Gland Pharma's sterile injectable portfolio, potentially bolstering long-term revenue growth.

What just happened

Gland Pharma has officially received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Methylprednisolone Acetate Injectable Suspension. The approval covers both single-dose and multiple-dose vials in various concentrations, including 40 mg/mL and 80 mg/mL formulations. The product is a bioequivalent version of Pfizer Inc.’s Depo-Medrol.

Why this matters

This approval allows the company to tap into a significant market segment. According to IQVIA data for the twelve months ending August 2026, the US market for this specific injectable medication is valued at approximately USD 214 million. By entering this space, Gland Pharma continues to execute its strategy of scaling its footprint in the competitive US generic sterile injectables sector.

Medical applications

The approved medication is used to treat a wide variety of medical conditions. These include endocrine disorders, rheumatic disorders, respiratory diseases, dermatologic issues, and several systemic illnesses, making it a versatile addition to the company's product basket.

What to track next

Investors should monitor the company’s manufacturing timeline and commercial launch schedule for this product in the US. Sustained growth in the US market remains a key driver for Gland Pharma’s revenue performance, and further ANDA approvals are expected to be the primary indicator of the firm's operational momentum.